| [ Summary ] |
Recently, endoscopic submucosal dissection (ESD) has become a standard therapy in Japan for treatment of early gastric cancer (EGC). This technique has become widely used and is gaining acceptance in other countries as well. Based on retrospective data, the risk of lymph node metastasis in EGC is thought to be relatively low. A phase II trial of ESD (Japanese Clinical Oncology Group [JCOG] 0607 study) has been initiated to evaluate the efficacy and safety of ESD for EGC. Outcomes assessed in this study included 5‒year overall survival, overall survival in cases without ulcerative lesions, overall survival in cases with ulcerative lesions, recurrence‒free survival, 5‒year recurrence‒free survival, proportion of 1‒piece resection, proportion of pathological curative resection after endoscopic mucosal resection, adverse events, and serious adverse events. In the future, further expansion of the indication for ESD should be evaluated. |